Slingshot members are tracking this event:

Regeneron Announces Agreement with BARDA for the Manufacturing and Testing of New Antibodies Against MERS Virus

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details HHS will provide funding to Regeneron of up to $8.9 million to support packaging and labeling of the antibodies for human use (known as "fill and finish"), the preparation and submission of an Investigational New Drug application with the U.S. Food and Drug Administration (FDA), and a National Institutes of Health-conducted clinical trial in healthy volunteers. Currently there are no approved medicines or vaccines to treat or prevent MERS, which causes severe respiratory tract infections and is associated with high death rates. Cases of MERS have been reported in the Middle East, South Korea, Europe, the United States, Africa and other countries in Asia.  
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 22, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Mers Virus, Antibody Candidates, Zika, Ebola